# Phosphate, Calcium, Magnesium

## Phosphate

The usual reason to measure urinary phosphate excretion is to distinguish renal from extra-renal phosphate wasting in chronic hypophosphataemia.  Renal phosphate wasting may occur in isolation or as part of a Fanconi syndrome (Imel & Econs, JCEM 2012).  

### Measuring urinary phosphate and calculating TmP/GFR {#TMPGFR}

A fasted, morning sample is preferred to minimise the effects of circadian and post-prandial changes in phosphate and creatinine (Imel & Econs, JCEM 2012).  

\BeginKnitrBlock{algpanel}<div class="algpanel">#### Spot urine sample to measure phosphate excretion {-}  
- fast overnight; discard the first urine void of the day  
- collect second voided urine of the day and a paired blood sample  
- send blood for U&Es, phosphate (and often also HCO~3~, calcium, alkaline phosphatase, PTH, vitamin D...)  
- send urine for U~Cr~ and U~PO4~ (and often also calcium)  
- interpret results by calculating TRP or TmP/GFR  
</div>\EndKnitrBlock{algpanel}

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">\begin{equation}
  \text{fractional excretion of phosphate, }FE_{PO_{4}} = \frac{U_{PO_{4}}}{P_{PO_{4}}} \times \frac{P_{Creat}}{U_{Creat}}
  (\#eq:FEPO4)
\end{equation}

\begin{equation}
  \text{tubular re-absorption of phosphate, }TRP = 1 - FE_{PO_{4}}
  (\#eq:TRP)
\end{equation}
</div>\EndKnitrBlock{eqnpanel}

It may be preferable to express results in terms of the **maximum reabsorption rate** of phosphate, TmP.  Because net phosphate transport will be largely determined by filtered load, this is usually expressed per unit volume of glomerular filtrate: as **TmP/GFR**.  TmP is a *rate* of transport (mg per min); GFR is a rate of flow (ml per min); therefore TmP/GFR is a concentration (mg/ml or mM).  This concentration is the P~PO4~ threshold above which phosphate will appear in the urine (Bijvoet et al, Clinica Chemica Acta 1969).  

This measure is conceptually complex, but offers a number of potential advantages: 

i) it represents a relevant physiological paramater (the capacity of the renal tubule to re-absorb phosphate)  

ii) there are well-defined, age-specific reference ranges (see below)  

Strictly speaking, TmP/GFR can only be determined by subjecting individuals to continuous intravenous phosphate infusions.  However, it can be estimated from the TRP using one of two methods.  

The first is to consult a Walton-Bijvoet *nomogram* (Imel & Econs, JCEM 2012).

The second is to use an *equation* derived by Kenny & Glen (Payne, Ann Clin Biochem 1998): 

\BeginKnitrBlock{eqnpanel}<div class="eqnpanel">If TRP $\leq$ 0.86 then values lie on linear portion of curve and...

\begin{equation}
  \text{TmP/GFR} = TRP \times P_{PO_{4}}
  (\#eq:TmPGFRone)
\end{equation}

            
If TRP > 0.86 then values lie on splay and...

\begin{equation}
  \text{TmP/GFR} = \alpha \times P_{PO_{4}}
  (\#eq:TmPGFRtwo)
\end{equation}
      
...where,

\begin{equation}
  \alpha = \frac{0.3 \times TRP}{1 - (0.8 \times TRP)}
  (\#eq:TmPGFR2alpha)
\end{equation}
</div>\EndKnitrBlock{eqnpanel}

There is some evidence that using the equation is less likely result in errors (Barth et al., Ann Clin Biochem 2000).  

### Reference ranges

As a general rule, TRP < 0.8 is abnormal (or < 0.9 if P~PO4~ < 0.8 mM).  

Age-specific reference ranges for TmP/GFR have been reported (e.g. see Payne, Ann Clin Biochem 1998).  These are approximately the same as reference ranges for P~PO4~.  

### Causes of hypophosphataemia  

The differential diagnosis and diagnostic approach is reviewed by Imel & Econs (JCEM, 2012).  

Broadly, hypophosphataemia may be due to:  

<!-- a) transcellular shifts (TmP/GFR not low):  -->
<!--   - respiratory alkalosis  -->
<!--   - re-feeding syndrome   -->

<!-- b) impaired GI absorption (TmP/GFR not low):  -->
<!--   - poor dietary intake  -->
<!--   - malabsorption (including in EtOH XS)  -->
<!--   - vitamin D deficient / impaired signalling  -->
<!--   - phosphate binders (including antacids)   -->

<!-- c) renal losses (TmP/GFR low):  -->
<!--   - FGF23-dep: inherited (e.g. XLH, fibrous dysplasia...)  -->
<!--   - FGF23-dep: acquired (e.g. tumour-associated osteomalacia, post-renal transplant...)  -->
<!--   - FGF23-indep: without Fanconi (hyperPTH, diuretics, HHRH)  -->
<!--   - FGF23-indep: with Fanconi syndrome (inherited or acquired)   -->

<table>
<tbody>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="2"> TRANSCELLULAR SHIFTS (TMP/GFR NOT LOW) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;"> respiratory </td>
   <td style="text-align:left;"> respiratory alkalosis </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;"> metabolic </td>
   <td style="text-align:left;"> re-feeding syndrome </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="4"> IMPAIRED GI ABSORPTION (TMP/GFR NOT LOW) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="3"> vit D-indep </td>
   <td style="text-align:left;"> poor dietary intake </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> malabsorption (including in EtOH XS) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> phosphate binders (including antacids) </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;"> vit D-dep </td>
   <td style="text-align:left;"> vitamin D deficient / impaired signalling </td>
  </tr>
  <tr>
   <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="4"> RENAL LOSSES (TMP/GFR LOW) </td>
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="2"> FGF23-dep </td>
   <td style="text-align:left;"> inherited (e.g. XLH, fibrous dysplasia…) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> acquired (e.g. tumour-associated osteomalacia, post-renal transplant…) </td>
  </tr>
  <tr>
   
   <td style="text-align:left;font-style: italic;background-color: white !important;vertical-align: top !important;" rowspan="2"> FGF23-indep </td>
   <td style="text-align:left;"> without Fanconi (hyperPTH, diuretics, HHRH) </td>
  </tr>
  <tr>
   
   
   <td style="text-align:left;"> with Fanconi syndrome (inherited or acquired) </td>
  </tr>
</tbody>
</table>

## Calcium

Urine calcium excretion will vary according to calcium intake and urinary sodium excretion (with UCa and UNa changing in parallel) (Foley & Boccuzzi, 2010).  

Urine calcium excretion is best assessed on 24 hr collection, rather than spot samples.  

Results may be expressed either as:  

- total calcium excretion (as mg per kg BW per day)  
- 24hr calcium-creatinine clearance ratio, CCCR  
- calcium / creatinine excretion ratio (as mg/mg or mmol/mmol)  

The CCCR is often referred to as the FE~Ca~, but given the extent to which serum calcium is protein-bound, it may not be appropriate to think of it as such.  

CCCR performs best as a screening test for familial hypocalciuric hypocalcaemia (Christensen et al, Clin Endo 2008).  

Random spot urine samples may be used (but are less accurate) and are normally interpreted as:  

- calcium / creatinine ratio (mg/mg or mmol/mmol)


### Interpreting the results   

#### Unit conversions

Ca: 1 mg = 0.025 mmol
Cr: 1 mg = 0.0088 mmol

Therefore, a Ca/Cr of x mg/mg = 2.84x mmmol/mmol.  

#### Normal calcium excretion:  

- 1--4 mg/kg/day (0.025--0.1 mmol/kg/day)
- Ca/Cr ratio < 0.14 mg/mg

#### Hypercalciuria (e.g. in hyperPTH, other causes of hypercalcaemia, RTA):  

+ \>4 mg per kg per day
+ \>300 mg (= 7.50 mmol) per day (men) or >250 mg (= 6.25 mmol) per day (women)  
+ Ca/Cr ratio > 0.20 mg/mg (adults) - or > 0.15 in second void urine after an overnight fast    
+ FE~Ca~ > 2 % (CCCR > 0.020)


#### Hypocalciuria (e.g. FHH, Gitelman):  

+ FE~Ca~ < 1 % (CCCR < 0.010)

In a small Japanese cohort of adult patients with Gitelman syndrome, calcium excretion was ~ 10-fold lower than in matched controls (Cheng et al, AKJD 2007):  

- 24hr excretion \~20 *vs* \~200 mg
- FE~Ca~ \~0.15% *vs* \~1.5%  
- Ca/Cr \~0.006 *vs* \~0.06 mg/mg (= \~0.02 *vs* \~0.2 mmol/mmol)  


## Magnesium

Kidney is the major regulator; 90 % in stores (bone / muscle).

FE~Mg~ (divide by 0.7).  This is because P~Mg~ is multiplied by 0.7 to account for protein binding; only 70% of circulating Mg is free and therefore able to be filtered; 30% is albumin-bound (Agus, JASN 1999).  

FE~Mg~ \> 4 % = renal loss.

PPIs cause hypoNa, hypoK, hypoMg, hypoPO4.  FE~Mg~ can be a useful diagnostic test.  

### Differential diagnosis of hypomagesaemia

<!-- +  with hyperK  -->
<!--     +  *CNIs*  -->
<!--     +  *K-sparing diuretics*  -->
<!--     +  *poorly-controlled DM*   -->
<!-- +  with hypoK  -->
<!--     +  *PPIs*  -->
<!--     +  *diuretics (loop / thiazides)*  -->
<!--     +  *Bartter / Gitelman*  -->
<!--     +  *Conn*  -->
<!--     +  *amphotericin*   -->
<!-- +  with hypoCa  -->
<!--     +  *PPIs*  -->
<!--     +  *post-parathyroidectomy*  -->
<!--     +  *TRPM6 / claudin 16 mutations*   -->
<!-- +  isolated (rare)  -->
<!--     +  *EGF / NaKATPase-γ mutations*  -->
    
    <table>
    <tbody>
      <tr>
       <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="5"> with hypoK </td>
       <td style="text-align:left;"> PPIs </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> diuretics (loop / thiazides) </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> Bartter / Gitelman </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> Conn </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> amphotericin </td>
      </tr>
      <tr>
       <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="3"> with hyperK </td>
       <td style="text-align:left;"> CNIs </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> K-sparing diuretics </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> poorly-controlled DM </td>
      </tr>
      <tr>
       <td style="text-align:left;font-weight: bold;background-color: white !important;vertical-align: top !important;" rowspan="3"> with hypoCa </td>
       <td style="text-align:left;"> PPIs </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> post-parathyroidectomy </td>
      </tr>
      <tr>
       
       <td style="text-align:left;"> TRPM6 / claudin 16 mutations </td>
      </tr>
      <tr>
       <td style="text-align:left;font-weight: bold;background-color: white !important;"> isolated (rare) </td>
       <td style="text-align:left;"> EGF / NaKATPase-γ mutations </td>
      </tr>
    </tbody>
    </table>
    
